Biotech | February 17, 2022
Pebble engages MD Anderson to evaluate multi-cannabinoid formulations in ovarian cancer
Despite advances over the past 20 years, ovarian cancer treatment requires better standard of care
Despite advances over the past 20 years, ovarian cancer treatment requires better standard of care
The construction is scheduled to begin in the third quarter of the calendar year 2022, with expected completion in early 2024
The supplemental adolescent approval enhances Solosec’s strong position as the first and only single-dose oral prescription antimicrobial agent approved for the treatment of both trichomoniasis and BV
Funding will support continued advancement of Centauri’s antimicrobial resistance research to identify novel therapeutic candidates using its proprietary Alphamer platform
Application based on the pivotal Phase 3 TRANSFORM study in which Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years
TRIS AMINO HCl is widely used as a diagnostic reagent and as a downstream processing buffer in the purification of commercial biopharmaceuticals
The device will facilitate the treatment of cerebral vasospasm following hemorrhagic stroke
The capex during the last nine months has been around Rs 110 crores which is all funded through internal accruals
The funds will be used to expand digital product offerings, grow their online customer base, and launch their flagship clinic in Bengaluru
BDR Pharmaceuticals is a home-grown company with operations in India and overseas. It’s known for its formulations portfolio and has a presence in specialty medicines. The company has ambitious plans as it has ramped up capacity and looking to foray into regulated markets. Raheel Shah, Director, BDR Group of Companies shares his insights in an interview with Thomas C Thottathil, Editor, Indian Pharma Post
Subscribe To Our Newsletter & Stay Updated
